News
ERAS
10.46
+0.77%
0.08
The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift
Simply Wall St · 15h ago
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Barchart · 1d ago
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 1d ago
Erasca Price Target Cut to $26.00/Share From $28.00 by Mizuho
Dow Jones · 1d ago
Erasca Is Maintained at Outperform by Mizuho
Dow Jones · 1d ago
Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26
Benzinga · 1d ago
Erasca price target lowered to $26 from $28 at Mizuho
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS), Canopy Growth (CGC) and Alkermes (ALKS)
TipRanks · 2d ago
Piper Sandler Remains a Buy on Erasca (ERAS)
TipRanks · 2d ago
Analyst Reiterates Buy on ERAS-0015’s Emerging Pan-RAS Potential; $20 Price Target Maintained
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Erasca (ERAS), Liquidia Technologies (LQDA) and DocGo (DCGO)
TipRanks · 2d ago
Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks
Seeking Alpha · 2d ago
Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate
Benzinga · 2d ago
Erasca reports Q1 EPS (60c), consensus (23c)
TipRanks · 2d ago
Erasca GAAP EPS of -$0.60
Seeking Alpha · 2d ago
Erasca Q1 net loss widens on higher R&D costs
Reuters · 2d ago
*Erasca Cash, Cash Equivalents, and Marketable Securities of $409 M as of March 31; Expected to Fund Ops 2H 2028 >ERAS
Dow Jones · 2d ago
*Erasca 4Q Loss/Shr 60c >ERAS
Dow Jones · 2d ago
Erasca Q1 FY26 net loss widens to $183.4 million###
PUBT · 2d ago
ERASCA REPORTS FIRST QUARTER 2026 BUSINESS UPDATES AND FINANCIAL RESULTS
Reuters · 2d ago
More
Webull provides a variety of real-time ERAS stock news. You can receive the latest news about Erasca, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.